Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Updates On Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

Nov 5 (Reuters) - Zai Lab Ltd 9688.HK:

UPDATE ON AMGEN'S BEMARITUZUMAB PHASE 1B/3 FORTITUDE-102 STUDY

AMGEN STOPS PHASE 1B/3 TRIAL FOR INADEQUATE EFFICACY

Further company coverage: 9688.HK

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news